Press Release: European Medicines Agency recommends suspension of Octagam in all EU Member States

Author (Corporate)
Series Title
Series Details EMA/CHMP/591722/2010 (23.9.10)
Publication Date 23/09/2010
Content Type

The European Medicines Agency (EMA), on 23 September 2010, recommended the suspension of the marketing authorisations for Octagam (human normal immunoglobulin), from Octapharma GmbH and a recall of Octagam currently on the market in Europe. As the medicine will no longer be made available, the Agency recommends that doctors should stop using Octagam and should switch their patients to the most appropriate alternative treatment.
Source Link Link to Main Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001123.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp
Related Links
EMA: Press Release: EMA/297816/2011 (14.4.11): European Medicines Agency recommends lifting of suspension of Octagam http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/04/WC500105247.pdf
EMA: Press Release: EMA/CHMP/591722/2010 (23.10.10): European Medicines Agency recommends suspension of Octagam in all EU Member States http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/09/WC500097037.pdf
Subject Categories
Countries / Regions